.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin caused strengthened progression-free and also total survival, resulting in FDA commendation and a new therapy option for clients.